Pembrolizumab’s Perioperative Power in Head and Neck Cancer
Adding pembrolizumab before and after surgery to standard of care improved outcomes in previously untreated head and neck cancer patients.
Adding pembrolizumab before and after surgery to standard of care improved outcomes in previously untreated head and neck cancer patients.
This award, honoring Dr. Joseph H. Burchenal, recognizes outstanding achievements in clinical cancer research.
Air pollution, both indoors and outdoors, is a leading cause of lung cancer, especially among nonsmokers.
This award recognizes an individual in any sector who has significantly contributed to any aspect of pediatric cancer research.
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
thursday, September 18 Conference Registration 1:30-7:00 p.m. Welcome and Opening Session 4-6 p.m. | CME-eligible Minorities in Cancer Research (MICR) Meet and Greet 6-7 p.m.…
Meeting overview details for AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research – Emerging Science Driving Transformative Solutions
As a patient, survivor, or caregiver, your story can provide hope and inspiration to someone who’s been diagnosed with cancer or is undergoing therapy.
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Air pollution, both indoors and outdoors, is a leading cause of lung cancer, especially among nonsmokers. by William G. Nelson, MD, PhD After hearing about…
This award will recognize a worthy cancer researcher who has conducted highly meritorious translational and clinical cancer research anywhere in the world.